dabigatran, rivaroxaban, apixaban or edoxaban
Pre-clinicalUNKNOWN 0 watching 0 views this week๐ค Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Atrial Fibrillation
Conditions
Atrial Fibrillation, Recurrent Venous Thromboembolism
Trial Timeline
Jul 29, 2019 โ Aug 1, 2024
NCT ID
NCT04042155About dabigatran, rivaroxaban, apixaban or edoxaban
dabigatran, rivaroxaban, apixaban or edoxaban is a pre-clinical stage product being developed by Daiichi Sankyo for Atrial Fibrillation. The current trial status is unknown. This product is registered under clinical trial identifier NCT04042155. Target conditions include Atrial Fibrillation, Recurrent Venous Thromboembolism.
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04042155 | Pre-clinical | UNKNOWN |
Competing Products
20 competing products in Atrial Fibrillation